| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1374281 | Bioorganic & Medicinal Chemistry Letters | 2010 | 4 Pages |
Abstract
A novel series of arylindenopyrimidines were identified as A2A and A1 receptor antagonists. The series was optimized for in vitro activity by substituting the 8- and 9-positions with methylene amine substituents. The compounds show excellent activity in mouse models of Parkinson’s disease when dosed orally.
Graphical abstractA novel series of arylindenopyrimidines were identified as A2A and A1 receptor antagonists. The series was optimized for in vitro activity by substituting the 8- and 9-positions with methylene amine substituents. The compounds show excellent activity in mouse models of Parkinson’s disease when dosed orally.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Brian C. Shook, Stefanie Rassnick, Daniel Hall, Kenneth C. Rupert, Geoffrey R. Heintzelman, Kristen Hansen, Devraj Chakravarty, James L. Bullington, Robert H. Scannevin, Brian Magliaro, Lori Westover, Karen Carroll, Lisa Lampron, Ronald Russell,